ImmPACT Bio Granted FDA Fast Track Designation for IMPT-514 for the Treatment of Both Active, Refractory Lupus Nephritis and Systemic Lupus Erythematosus
ImmPACT Bio Granted FDA Fast Track Designation for IMPT-514 for the Treatment of Both Active, Refractory Lupus Nephritis and Systemic Lupus Erythematosus IMPT-514 is the first CD19/CD20 CAR T-cell therapy in development for lupus Designed as a one-time treatment option, IMPT-514 has potential to reset the immune system through deep autoreactive B-cell depletion Dosing of […]
ImmPACT Bio to Present at Cell & Gene Meeting on the Mesa
ImmPACT Bio to Present at Cell & Gene Meeting on the Mesa LOS ANGELES, Calif., October 3, 2023 – ImmPACT Bio USA, Inc. (“ImmPACT BIO”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced that it will participate at the 2023 Cell & Gene […]
ImmPACT Bio Doses First Patient in Phase 1/2 Trial Evaluating IMPT-314, a Bispecific CD19/CD20 CAR T-cell Therapy for the Treatment of Aggressive B-cell Lymphoma
ImmPACT Bio Doses First Patient in Phase 1/2 Trial Evaluating IMPT-314, a Bispecific CD19/CD20 CAR T-cell Therapy for the Treatment of Aggressive B-cell Lymphoma Potential best-in-class dual-targeting CAR T-cell therapy designed to limit antigen escape and serious adverse events for improved tolerability, durability, and accessibility IMPT-314 granted Fast Track Designation from U.S. Food and Drug […]
Manufacturing of CD19/CD20 Bispecific CAR-T Cell Therapy (IMPT-514) for the Treatment of Systemic Lupus Erythematosus
Chen X, et al. Poster presentation at the 8th Annual CAR-TCR Summit in Boston. August 2023
ImmPACT Bio Announces FDA Clearance of IND Application for Bispecific CD19/CD20 CAR T Therapy IMPT-514 for the Treatment of Refractory Systemic Lupus Erythematosus
Dual CD19 and CD20-targeting CAR T therapy offers broad immune targeting and potential to reset immune system No neurotoxicity and only Grade 1 cytokine release syndrome in ongoing UCLA investigator-led study in lymphoma West Hills, Calif., August 15, 2023 – ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen […]
